Top pharma companies by revenues in 2023| Best Selling Drugs of 2023 |Top 20 pharma companies | iPharmaCenter
- ipharmaservices
- Jan 30, 2024
- 10 min read
Updated: Feb 10, 2024
TOP PHARMACEUTICAL COMPANIES BY REVENUES 2023
Merck revenues exclude animal health revenues
1. JOHNSON AND JOHNSON
Q1 REVENUES
Johnson and Johnson reported Q1 revenues for 2023.
The company reported revenues of $24.7 billion, an increase of 5.6% versus 2022 ($23.4 billion).
The consumer health revenues were $3.8 billion, pharmaceutical revenues were $13.4 billion, and MedTech revenues were $7.5 billion.
The best-selling products are Stelara ($2.4 billion), Darzalex ($2.2 billion), Imbruvica ($0.83 billion), and Tremfya ($0.64 billion).
Q2 REVENUES
Johnson & Johnson has released its financial results for the second quarter of 2023. During this period, the company reported a sales growth of 6.3% to reach $25.5 billion.
In the pharmaceutical segment, worldwide adjusted operational sales experienced a growth of 3.9%. However, when excluding the COVID-19 vaccine from the equation, the adjusted operational sales grew by a more substantial 6.2%. The growth in this area was driven by the success of key drugs such as Darzalex, contributing $2.4 billion in revenue; Stelara, with $2.8 billion; and Tremfya, with $706 million.
In the first half of 2023, Johnson & Johnson's total revenues reached $50.3 billion.
Among their best-selling drugs were Darzalex, bringing in $4.7 billion in revenue, and Imbruvica, contributing $1.7 billion.
Q3 REVENUES
During the third quarter of 2023, Johnson and Johnson reported a 6.8% increase in reported sales, amounting to $21.4 billion.
The revenues from the first nine months were $63.8 billion.
Specifically, within the Innovative Medicine segment, the company achieved a commendable 4.4% growth in adjusted operational sales on a global scale. Excluding the contribution from the COVID-19 Vaccine, operational sales witnessed a surge of 8.2%.
Best selling products (until Q3 2023)
Q4 REVENUES
In the last quarter of 2023, there was a reported increase in sales by 7.3%, reaching a total of $21.4 billion. The operational growth was 7.2%, and the adjusted operational growth stood at 5.7%. Excluding the impact of the COVID-19 Vaccine, the operational growth was 10.9%.
BEST SELLING PRODUCTS OF J&J IN 2023
Stelara | $ 10.9 billion |
Darzalex | $ 9.7 billion |
Invega product | $ 4.1 billion |
Imbruvica | $ 3.2 billion |
Tremfya | $ 3.1 billion |
2. ROCHE
Q1 RESULTS
Roche reported a drop in revenues by 3% at CER. However, the pharmaceutical division saw an increase in revenues by 9%, while there was a drop of 28% in the diagnostics division.
The pharmaceutical division revenues were $13.2 billion. The best-selling products were Ocrevus ($1.8 billion), Perjeta ($1.2 billion), Hemlibra ($1.2 billion), Tecentriq ($1.0 billion), and Actemra ($0.8 billion).
Q3 RESULTS
Roche presented Q3 financial results, reporting total revenues of CHF 14.3 billion. The cumulative revenues in the first nine months amounted to CHF 44 billion ($ 48.9 billion).
The company consistently grew in group sales, with a 1% increase at constant exchange rates (CER) throughout the first nine months. This growth gained substantial momentum in the third quarter, with a remarkable 7% surge.
Within the Pharmaceuticals Division, sales saw a notable upswing of 9%, primarily attributed to the sustained high demand for newer medications. Meanwhile, the Diagnostics Division experienced a 7% increase in its base business, albeit the overall divisional sales registered an 18% decrease.
In the third quarter, Roche's top-performing pharmaceuticals included Ocrevus, which generated CHF 1.6 billion; Hemlibra with CHF 1.0 billion, Perjeta at CHF 913 million; and Actemra, which brought in CHF 647 million in revenue.
Ocrevus emerged as Roche's best-selling product, capturing a remarkable 24% share of the global multiple sclerosis market and accumulating revenues of CHF 4.8 billion during the first nine months of 2023.
3. PFIZER
Q1 RESULTS
Pfizer reported a 29% drop in revenues for the first quarter. Comirnaty revenues dropped by 75%, resulting in $3.0 billion, while Paxlovid revenues reached $4.0 billion. Other best-selling drugs included Eliquis ($1.9 billion), the Prevnar family ($1.6 billion), and Ibrance ($1.1 billion).
Q2 RESULTS
Pfizer's financial performance in the second quarter of 2023 has been reported, reflecting revenues of $12.7 billion. The primary factor contributing to this quarter's 53% operational decrease in revenue was the anticipated decline in Paxlovid and Comirnaty revenues.
Consequently, the company has revised its revenue guidance for the full year 2023 to $67 to $70 billion, adjusting its expectations for non-COVID operational revenue growth to fall between 6% and 8%.
In the initial half of 2023, Pfizer's total revenues amounted to $31 billion. The significant revenue drivers during this period included Comirnaty with $4.5 billion, Paxlovid with $4.2 billion, Eliquis contributing $3.6 billion, the Prevnar family of products generating $3.0 billion, and Ibrance with $2.4 billion in revenue.
Q3 RESULTS
In its third-quarter report, Pfizer announced revenues totaling $12.9 billion, signifying a notable 42% decrease compared to the same period in 2022. This decline is primarily attributed to decreased revenues from Comirnaty and Paxlovid.
Over the initial nine months of the year, Pfizer's reported revenues amounted to $44.2 billion, marking a 42% reduction compared to the previous year's figures.
Q4 REVENUES
In the fourth quarter of 2023, the revenues amounted to $14.2 billion, indicating a decrease of $10.0 billion, or 41%, in comparison to the corresponding quarter of the previous year. This decline is attributed to an operational decrease of $10.1 billion, or 42%, largely influenced by a substantial reduction in global revenues from Comirnaty and Paxlovid.
BEST SELLING PRODUCTS OF PFIZER IN 2023
Comirnaty | $ 11.2 billion |
Eliquis | $ 6.7 billion |
Prevnar family | $ 6.4 billion |
Ibrance | $ 4.7 billion |
4. MERCK
Q1 RESULTS
Merck's pharmaceutical segment experienced a decrease of 10%, with first-quarter revenues at $12.7 billion due to the reduced demand for Lagevrio. However, Keytruda revenues grew at an impressive 20%, generating $5.8 billion in revenue. Other growth drivers for Merck were Gardasil/Gardasil 9 at $2.0 billion and Januvia at $0.88 billion.
Q3 REVENUES
In the third quarter of 2023, the pharmaceutical department reported revenues of $14.2 billion. Over the first nine months of the year, the total revenue reached $40.4 billion. Notably, the company's top-selling products for this period were Keytruda, generating $18.4 billion in revenue, followed by Gardasil/Gardasil 9 at $7.0 billion, and Januvia, which contributed $1.6 billion to the company's earnings.
Q4 REVENUES
In the fourth quarter of 2023, Merck's pharmaceutical segment witnessed a revenue of $13.14 billion, marking an 8% growth from the previous year. This positive trajectory was fueled by advancements in oncology, vaccines, and hospital acute care. However, it faced challenges with a decline in virology, attributed to factors like Lagevrio, and diabetes.
For the entire year, Merck's revenues totaled $53.6 billion, reflecting a 1% increase compared to the preceding year.
Best selling drugs of Merck
Brand | Revenues in billions |
Keytruda | $ 25.0 billion |
Gardasil / Gardasil 9 | $ 8.9 billion |
5. ABBVIE
Q1 RESULTS
AbbVie reported revenues of $12.2 billion in the first quarter of 2023, down nearly 10%, primarily due to a significant drop in Humira's revenues. Immunology revenues fell by 9%, with Humira revenues at $3.5 billion, a 25% drop compared to the first quarter of 2022. US revenues dropped by 26%. Skyrizi and Imbruvica were the other growth drivers for AbbVie, with revenues of $1.3 billion and $0.88 billion, respectively.
Q2 REVENUES
AbbVie has released its financial results for the second quarter of 2023, showing net revenues of $13.9 billion, a decline of 4.9% on a reported basis and 4.2% on an operational basis. The global net revenues from the immunology portfolio in the second quarter were $6.8 billion, a decrease of 5.5% on a reported basis or 5.0% on an operational basis. Specifically, Humira's global net revenues amounted to $4.0 billion, Skyrizi's net revenues were $1.9 billion, and Rinvoq's net revenues reached $918 million.
In the first six months of 2023, AbbVie achieved total revenues of $26 billion, with significant contributions coming from Humira ($7.5 billion), Skyrizi ($3.2 billion), Imbruvica ($1.8 billion), and Rinvoq ($1.6 billion).
Q3 REVENUES
AbbVie's third-quarter report for 2023 has revealed a total revenue of $13.9 billion, marking a 6% decrease compared to the previous year. This decline in revenue can be primarily attributed to a significant drop in Humira sales, which saw a 36% decrease compared to the third quarter of 2022. Despite this setback, AbbVie had positive developments in its product portfolio, with Skyrizi generating $2.1 billion in revenue, and Rinvoq generating $1.1 billion, both reflecting an impressive increase of more than 50%.
Cumulatively, the first nine months of the year yielded revenues of $40.0 billion. AbbVie's best-selling products during this period included Humira, generating $11.0 billion in revenue, followed by Skyrizi at $5.4 billion, Imbruvica at $2.7 billion, and Rinvoq at $2.7 billion.
Q4 REVENUES
Total Net Revenues: AbbVie delivered full-year net revenues of $54.32 billion, showing a decrease of 6.4 percent on a reported basis and 5.9 percent on an operational basis.
Immunology Portfolio: Global net revenues from the Immunology Portfolio were $26.136 billion, reflecting a decrease of 9.6 percent on a reported basis or 9.2 percent on an operational basis. This decline is attributed to biosimilar competition for Humira. Global Humira's net revenues were $14.404 billion, while Skyrizi's net revenues were $7.763 billion, and Rinvoq's net revenues were $3.969 billion.
Oncology Portfolio: Full-year global net revenues from the Oncology Portfolio amounted to $5.915 billion, indicating a decrease of 10.1 percent on a reported basis or 9.8 percent on an operational basis. Global Imbruvica net revenues were $3.596 billion, and global Venclexta net revenues were $2.288 billion.
Neuroscience Portfolio: Full-year global net revenues from the Neuroscience Portfolio experienced an increase of 18.2 percent on a reported basis, reaching $7.717 billion.
Humira | $ 14.4 billion |
Skyrizi | $ 7.8 billion |
Rinvoq | $ 4.0 billion |
Imbruvica | $ 3.6 billion |
6. SANOFI
Q1 REVENUES
Sanofi's first quarter revenues were $11.3 billion, primarily driven by Dupixent at $2.5 billion.
Q2 REVENUES
Sanofi reported revenues of $11 billion in the second quarter of 2023.
Specialty Care experienced notable growth of 11.8%, primarily attributed to Dupixent, with revenues amounting to $2.8 billion, representing an increase of 34.2%.
Vaccines also performed well, achieving a growth of 9.1%. This growth was driven by robust sales of PPH vaccines in the Rest of the World and the supply of COVID vaccines in Europe.
In the first half of 2023, Sanofi's net revenues reached $22.2 billion, and the key driver behind this success was Dupixent, generating $5.4 billion in revenue. The company has expressed confidence in Dupixent, expecting it to generate revenues of $10 billion in 2023.
Q3 REVENUES
In the third quarter of 2023, Sanofi disclosed its Q3 revenues, reporting total sales of $12.6 billion. Notably, Dupixent played a significant role in these figures, contributing $3.0 billion in revenue during the third quarter.
When examining the company's performance over the first nine months of the year, Sanofi accumulated revenues totaling $34.0 billion.
Q4 REVENUES
Sanofi reported a robust sales growth of 9.3% at constant exchange rates (CER) in Q4 2023, accompanied by an 8.2% increase in business earnings per share (EPS). Speciality Care experienced a notable surge of 13.7%, propelled by the impressive performance of Dupixent and the launch of ALTUVIIIO, effectively countering generic competition for Aubagio in key markets.
Vaccine sales exhibited a significant uptick, soaring by 21.1%, primarily attributed to the unprecedented adoption of Beyfortus, reaching €410 million in the second quarter since its launch.
For the full year 2023, Sanofi delivered a commendable 5.3% growth in sales and a 5.4% increase in business EPS at constant exchange rates, with total sales reaching $46.4 billion. Dupixent played a pivotal role in driving this growth, contributing $11.55 billion with an impressive increase of 34.0%.
Vaccines also contributed to the positive trajectory, experiencing an 8.3% increase, boosted by the strong launch performance of Beyfortus, which generated $590 million in sales.
BEST SELLING DRUGS OF SANOFI
1 | Dupixent | $ 11.55 billion |
2 | Influenza vaccines | $ 2.9 billion |
7. NOVARTIS
Q1 RESULTS
Novartis reported revenues of $13.0 billion in the first quarter of 2023, with a growth of 8% at constant currency. The innovative medicines revenues increased by 7%, and Sandoz division revenues increased by 8%.
The company's best-selling products were Entresto ($1.4 billion) and Cosentyx ($1.1 billion).
Q2 RESULTS
Novartis reported revenues of $13.6 billion in the second quarter of 2023; in the first six months, the company reported revenues of $26.6 billion. In the second quarter, Novartis saw a 9% growth in sales (at CC) or 7% in USD terms. The core operating income also rose by 17% at constant currencies or 9% in USD terms.
The best-selling drugs of H1 2023 are Entresto ($2.9 billion), Cosentyx ($2.3 billion), Promacta/Revolade ($1.1 billion), and Tafinlar + Mekinist ($0.95 billion).
Q4 REVENUES
The company achieved total revenue of $45.4 billion for the entire year. Net sales experienced a notable growth of +10% (CC) and +8% in USD, while core operating income saw an impressive increase of +18% (CC) and +11% in USD. The sales increase was primarily attributed to the performance of products such as Entresto (+31% CC), Kesimpta (+99% CC), Kisqali (+75% CC), Pluvicto (+261% CC), and Scemblix (+179% CC).
Entresto | $ 6.0 billion |
Cosentyx | $ 5.0 billion |
8. BMS
Q1 REVENUES
Bristol-Myers Squibb (BMS) reported revenues of $11.3 billion, a 3% decrease. However, US revenues increased by 4%, driven primarily by Eliquis and Opdivo. The primary revenue drivers for BMS were Eliquis at $3.4 billion, Opdivo at $2.2 billion, and Revlimid at $1.7 billion.
Q2 REVENUES
Bristol Myers Squibb reported second-quarter revenues of $11.2 billion, which experienced a 6% decline. However, when adjusted for foreign exchange, the fall was 5%. This decrease was primarily attributed to lower sales of Revlimid. On the positive side, the decline was partially offset by steady sales from in-line products and the contribution of their new product portfolio.
In the international markets, revenues declined by 8% to reach $3.3 billion during the quarter. After adjusting for foreign exchange impacts, the decline was 6%. This decrease was primarily driven by the erosion of Revlimid and Eliquis due to generic competition and lower average net selling prices.
During the first six months, BMS announced total revenues of $22.56 billion. The primary contributors to this revenue were Eliquis, generating $6.6 billion, followed by Opdivo, with $4.3 billion. Additionally, Pomalyst and Orencia contributed reported revenues of $1.7 billion. Revlimid, the company's blockbuster, reported revenues of $3.2 billion during this period, a drop of 39%.
Q4 REVENUES
In the fourth quarter, Bristol Myers Squibb reported revenues of $11.5 billion. In-line and new product portfolio revenues saw a 9% increase, reaching $9.8 billion.
For the full year, the company disclosed revenues of $45.0 billion. In-line and new product portfolio revenues demonstrated a 7% increase, totaling $37.9 billion. Bristol Myers Squibb's overall revenues experienced a 2% decrease, both on a reported basis and when adjusted for foreign exchange. This decline was primarily attributed to reduced sales of Revlimid, partly offset by higher sales from the new product portfolio and Opdivo.
U.S. revenues saw a 1% decrease, amounting to $31.6 billion. This drop was mainly driven by lower sales of Revlimid due to generic erosion. Additionally, an increase in the number of patients receiving free drug products for Revlimid and Pomalyst from the Bristol Myers Squibb Patient Assistance Foundation, a distinct 501(c)(3) entity to which BMS donates products, contributed to the decline. However, this was partially counteracted by increased demand for Opdivo, Eliquis, and the new product portfolio.
International revenues experienced a 6% decrease, reaching $13.5 billion, or a 5% decrease when adjusted for foreign exchange impacts. This decline was primarily attributed to lower sales of Revlimid and Eliquis. Nonetheless, it was partially mitigated by an increase in demand for Opdivo and the new product portfolio.
Eliquis | $12.2 billion |
Opdivo | $9.0 billion |
Revlimid | $6.1 billion |
9. ASTRAZENECA
Q1 REVENUES
AstraZeneca's revenues for the first quarter of 2023 were $10.9 billion. Oncology revenues increased by 16%, with Tagrisso generating $1.4 billion, Imfinzi generating $0.9 billion, and Lynparza generating $0.65 billion. Biopharmaceutical revenue increased by 15%, with Farxiga generating $1.3 billion. The revenues from Soliris were $0.83 billion, and Ultomiris at $0.65 billion.
10. GSK
Q1 RESULTS
GSK reported revenues of $8.7 billion in the first quarter of 2023, with an increase of 15% in vaccine revenues and 9% in general medicines, whereas specialty pharmacy revenues dropped by 33%.
The revenues from Shingrix were $1.0 billion, and dolutegravir products were $1.6 billion.
Q4 REVENUES
In 2023, the total sales reached $38.2 billion, showing a 5% increase overall and a significant 14% growth when excluding the impact of COVID-19.
Vaccine sales saw a remarkable surge of 25%, rising to 24% when excluding the influence of the pandemic.
Dolutegravir products | $ 6.8 billion |
Shingrix | $ 4.4 billion |
Comments